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Abstract
Objective—To assess the quality of medical care in childhood-onset systemic lupus
erythematosus (cSLE) at tertiary pediatric rheumatology centers as measured by observance cSLE
quality indicators (cSLE-QI).
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Methods—International consensus has been achieved for cSLE-QI (Hollander et al. Arthritis
Care & Research, 2013) capturing medical care provision in nine domains: diagnostic testing,
education of cardiovascular (CV) risk and lifestyles, lupus nephritis (LN), medication
management, bone health, ophthalmological surveillance, transition, pregnancy and vaccination.
Using medical record information, the level of performance these cSLE-QI was assessed in cSLE
populations treated at four tertiary pediatric rheumatology centers in the U.S, two in Brazil, and
one center in India.
Results—A total of 483 cSLE patients were assessed. Care for the 310 U.S. patients differed
markedly for cSLE-QI addressing LN, bone health, vaccinations, education on CV risk, and
transition planning. Performance of safety blood testing for medications was high at all centers.
Despite often similar performance on the cSLE-QI, access to kidney biopsies was lower in Brazil
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than in the U.S. Irrespective of country of practice, larger centers tended to meet the cSLE-QI
more often than smaller centers.
Conclusions—The cSLE-QI, evidence based minimum standards of medical care, are not
consistently met in the U.S. or some other countries outside the U.S. This has the potential to
contribute to suboptimal cSLE outcomes.
Keywords
Childhood-onset SLE; Quality Indicator; quality of care; lupus; children
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The Institute of Medicine defined quality as “the step to which health services for
individuals and populations increase the probability of desired health consequences and are
reliable with current specialized knowledge” (1). Monitoring health care quality is virtually
impossible without the use of so-called quality indicators (QI), i.e. minimum standards of
medical care in support of optimal disease outcomes (2, 3).
Considering current medical knowledge and expert opinions, an international consensus has
been reached for a set of 26 QI to be used for children and adolescents with childhood-onset
systemic lupus erythematous (cSLE-QI) (4). The cSLE-QI address laboratory testing at the
time of cSLE diagnosis, general prevention, LN management, medication safety, bone
health, ophthalmologic surveillance, education about cardiovascular risk factors, pregnancy,
and neuropsychiatric manifestations (4).

Author Manuscript

It has been shown in the past for many diseases that treatment at large centers may support
the provision of medical care more reliably. Additionally, health disparity exists in pediatric
rheumatology care. It has been suggested that this affects medical care for adult-onset SLE
(5, 6) but it is unknown to which degree this affects basic cSLE medical care as can be
defined by the cSLE-QI. As a next step towards focusing research and quality improvement
efforts, benchmarking may help identify areas of health care that would benefit from added
attention in an effort to improve patient outcomes.
Hence, the objective of this study was to measure the performance of the cSLE-QI in
different regions of the world under consideration of differences in pediatric rheumatology
center size. Furthermore, only for the U.S sites we aimed at delineating the effects of public
and private insurance on the recommended medical care.

Author Manuscript

Materials and Methods
With the approval of institutional review boards of participating centers, cross-sectional
population-based data pertaining to the cSLE-QI were acquired based on information
provided in the medical records. A standardized data collection form (see supplemental table
online) with detailed completion instructions were used to ensure consistent recording of
events that only occur in quarterly or longer time intervals. The time frame for data
collection was October 2011 through June 2014.
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Each center provided data on every cSLE patient seen more than once for cSLE care in the
12-month period preceding the data extraction. To be included in the study, patients had to
fulfill Classification Criteria for SLE prior to the age of 18 years (7). Pediatric rheumatology
care at these centers was provided by physicians experienced and specifically trained in the
care of children with rheumatic diseases. The seven centers participating in this study were
self-selected.
Medical Record Review

Author Manuscript

Demographic information and insurance status were recorded. A QI item was only
considered to be met if there was written documentation that a certain education or test had
been performed. Information pertaining to cSLE-QI relevant to cSLE diagnosis was only
obtained for patients diagnosed within 18 months of data collection. Furthermore, to have
performed the cSLE-QI, any testing recommended at the time of cSLE diagnosis or that of
LN diagnosis had to be documented in the medical record within two clinic visits of the
index visit. LN flare was defined as worsening glomerular filtration rate or ongoing
proteinuria. For performance of safety laboratory evaluations, we focused on glucocorticoid
steroids (GCC) and hydroxychloroquine (HCQ). For the purpose of vaccination compliance,
we only assessed performance of influenza vaccination. For life-style modification QI, we
focused on smoking cessation (QI 24). Given the methodological approach taken,
information about the diagnostic approach to suspected cSLE could not be assessed, as is
considered in the first of the cSLE-QI.
Statistics
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We performed descriptive analysis and calculated percent of QI implementation per center.
We then assessed differences in cSLE-QI performance among U.S. centers, using CochranMantel-Haenzel test. Arbitrarily, centers treating at least 100 cSLE patients were considered
as large and those following fewer cSLE patients as small, respectively. Differences
between centers or categories of interest (large vs. small centers, U.S. private vs. public
insurance) was assessed using contingency table analysis with a continuity-corrected Chisquare or a Fisher exact test, if appropriate. Two-sided probabilities were assessed and pvalues < 0.05 were considered statistically significant. Analyses were done with SAS 9.3
statistical software, published by SAS Institute Inc., Cary, NC, USA.

Results
Patients

Author Manuscript

A total of 483 patients followed at seven centers were included in this study (Table 1). All
seven sites were at academic centers, with three considered as large sites and four as small
sites. All participating centers are at urban areas and all US sites have electronic medical
record. There were 2-5 providers in the small centers and about 4-15 providers in large
centers. Most patients were female. Notably, 178 patients from all of the sites were 18 years
or older. Renal involvement in the cohorts ranged from 30% to 71%. Pregnancies were rare,
and insurance status varied widely between sites, even in the same country.
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Performance of the cSLE-QI is presented in the sequence previously published by Hollander
et al. (4).
Laboratory Testing at Diagnosis—The cSLE-QI (QI 2) recommended standard
laboratory evaluation for children who newly carry the diagnosis of cSLE was documented
for almost all patients (Table 2).
General Prevention—The majority of the cSLE patients received the annual influenza
vaccination (QI 3). However, there was a considerable variability among sites. This was also
true for other cSLE-QI in this domain, namely education on sun avoidance, photoprotection,
and transition planning (QI 4 -5).

Author Manuscript

Lupus Nephritis and Hypertension Management—Most of the sites followed the
diagnostic procedures suggested for LN (QI 7 + 9). Exceptions were sites in Brazil with
apparent problems with access to kidney biopsies. Regular laboratory surveillance for LN
flares was performed inconsistently (QI 6 + 10), but immunosuppression for severe LN was
started promptly at the majority of the sites (QI 8).
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Medication Management—Explaining the risks and benefits of new medications for
cSLE was regularly performed and documented (QI 13). Conversely, HCQ prescription
varied between 75% to 100% at the participating sites (QI 14). Both GCC tapering efforts
(QI 15) and high-dose GCC usage differed widely among the participating sites (Table 1).
Introduction of immunosuppressive medications after failed GCC tapering (QI 16) was also
highly variable (25 to 100%) but the number of patients per site available to assess the
performance of this cSLE-QI was often small. However, sites generally performed the
recommend safety laboratory testing with medication usage (QI 17).
Bone Health—Assessment of bone mineral density at least once in every patient with
cSLE exposed to GCC differed widely among sites, ranging from 90% to 7% (QI 18). Lack
of repetition of dual-energy x-ray absorptiometry (DEXA), when warranted, was congruent
with the frequency of baseline DEXAs (QI 19). Calcium and Vitamin D supplementation
with chronic GCC use also differed widely among sites (QI 20).
Ophthalmological Surveillance—Documentation of regular eye examination in the
setting of HCQ and GCC use ranged from 96% to 72% of the patients at the participating
sites (QI 21+ 22).
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Education on Cardiovascular Risk Factors—The largest variability among sites was
observed for education on cardiovascular risk factors and life style modification (QI 23+24).
Pregnancy and Neuropsychiatric cSLE—There were a few pregnancies, making the
assessment of the observance of QI 25 difficult in this study. Immunosuppressive
medication usage in the setting of major Neuropsychiatric Systemic Lupus Erythematosus
(NPSLE) events was commonly done (QI 26).

Arthritis Care Res (Hoboken). Author manuscript; available in PMC 2017 February 01.

Mina et al.

Page 5

Differences in Performance of the cSLE- QI in the U.S

Author Manuscript

Table 3 presents cSLE-QI for which statistically significant differences in observance
among the participating U.S. sites were observed. Among the 25 QIs assessed, there were 14
(14/25 = 56%) with important differences among the four U.S. sites. The largest variability
was noted for QIs that address education on cardiovascular risks (QI 23 + 24) and calcium/
vitamin D supplementation with GCC use (QI 20).
Larger sites more consistently provide the recommended medical care to cSLE patients
As is summarized in Table 4, for 13 of the 25 QIs (13/25 = 52%) assessed there were
statistical significant differences in observance between large (N=3) and smaller (N=4) sites.
Generally, larger sites performed the QIs more frequently than smaller sites, with the
exception of the recommended work-up at the time of LN diagnosis (QI 7).

Author Manuscript

Public vs. private health insurance in the U.S
Given known differences in the health insurance systems between countries, we only
assessed whether there were differences in the quality of medical care by insurance status in
the U.S. Besides rare patients without insurance, there were cSLE patients whose care was
covered by private (n=189) and public insurance (n=112). There were no statistically
significant differences in any of the cSLE-QI when compared by insurance groups.

Discussion

Author Manuscript

QI can be considered minimum standards of recommended medical care. In order to guide
quality improvement efforts, benchmarking is required to delineate areas of greatest need for
intervention. In a study of cSLE patients followed at tertiary rheumatology centers in the
U.S., Brazil and India, we found statistically significant differences in the observance to
cSLE- QI within the U.S. and also between larger and smaller centers.
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Physicians across centers consistently ordered laboratory tests necessary in accordance to
the two cSLE-QI addressing drug safety surveillance. Conversely, there was marked
variation in the frequency patients of influenza vaccination. Given the increased risk of
infections with cSLE, vaccinations are highly relevant for patient safety and disease control.
Notably, there are documented suboptimal responses to at least some vaccinations with
cSLE (8). Therefore, cSLE patients should likely follow vaccination schedules that are
recommended for immunocompromised populations. Potential barriers to vaccinations are a
lack of affordability or reimbursement and potential deleterious effects of vaccine on disease
itself. No severe vaccine or disease-specific adverse events have been observed in cSLE
patients who have been vaccinated with non-live agents in a recent narrative review,
reinforcing the vaccine safety for this population (9). Possible approaches to improve
vaccination rates include training of pediatricians and pediatric rheumatology providers
about optimal vaccination practices. Additionally, education of families of children and
young adults with cSLE about the benefits of vaccinations seems warranted.
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It is well known that sun and other light exposure is associated with SLE disease flares (10).
Hence, photo protection education should be a critical part of care, but it was not
consistently done at many of the participating centers.
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Due to differences in the needs of children and adults with SLE, patients are transferred to
adult providers generally after their 18th birthday, although the exact age when the adult
rheumatology commences care is influenced by many factors. Difficulties with transfer of
care are supported by the findings of our study that a considerable proportion of cSLE
patients age 18 or even 21 years and older continued to receive treatment at pediatric
facilities. Transition planning seemed to constitute a challenge across all of the participating
U.S. centers. Best transition practices are an intense focus of research and are influenced by
not only patient factors but also health system factors (11). The former comprise patient selfmanagement skills and disease activity while the latter include access to adult providers,
medications and required social support. Not all the sites have transition program in place.
Both Brazilian centers have dedicated transition clinics for cSLE patients age 18 years or
older with proven self-management skills.
The recommended work-up for LN, including a kidney biopsy, was well established across
U.S. centers. Conversely, kidney biopsies were more difficult to obtain at the participating
Brazilian sites. Time intervals at which patients with LN were assessed at the U.S. pediatric
rheumatology centers were often longer than recommended, possibly suggesting problems
with access to care.
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In support of effective patient self-management, detailed discussion of risks and benefits of
new medications is important and was generally provided by the physicians. The same held
true for ordering the recommended laboratory testing for surveillance of drug safety.
Antimalarial usage was provided to the vast majority of cSLE patients, with larger
variability at non-U.S. sites. This may reflect difficulties in paying for such medications out
of pocket. Likewise, tapering of high-dose GCC generally was attempted but, if
unsuccessful, did not always result in prescribing GCC-sparing treatments. Reasons may be
cost or lack of viable therapeutic alternatives.
Monitoring of bone health with chronic use of GCC varied widely across centers and was
generally low in the U.S. and the participating site in India. This may expose patients to
long-term risks associated with osteoporosis. This is a special concern as sites with low
percentages of patients receiving monitoring of bone mineral density were also often not
prescribing the recommended calcium/vitamin D prophylaxis. Further, even closer
surveillance of patients with known low bone mineral density seems tenuous at best.
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Often education on cardiovascular risk factors was not performed consistently. Reasons
might include that cardiovascular events rarely occur while patients are under the care of
pediatric rheumatologists. Education for cardiovascular risk factors and observance of some
other cSLE-QI possibly may be better than the results we reported in our study since this is
based strictly on information recorded in the medical records. In line with this, several
centers indicated that the education referenced in these QI was provided but not
systematically documented in the record.
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We believe that inconsistent documentation is closely associated with inconsistent care
across patient populations. Indeed, when we evaluated the QI 4 (education on sun-exposure)
and considered education that was performed by physicians– to the best of their knowledge but had not been documented in the medical record (data not shown), the observance of QI 4
increased up to 46% at some sites. Dedicated recording space in the electronic medical
records improved documentation of all educational efforts. Lack of routine documentation
of QI 4 was twice as common in small as compared to larger sites (23% vs. 12%) with
marked variability at some sites.
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As has been reported from other areas of medicine, we observed that larger centers more
often reliably followed QI recommendations as compared to smaller centers. As such there
were statistically significant differences in frequency at which 14 of the 25 QI examined in
this study were followed, with smaller sites consistently showing lower endorsements. There
was one exemption (QI 7) where larger sites performed worse than the smaller ones and this
was due to limited access to kidney biopsies at the Brazilian sites.
While we found marked difference in QI performance among the tertiary U.S. pediatric
rheumatology centers that participated in this study, similar standards of care were provided
to patients with public as compared to private insurance. Thus health insurance status in the
U.S. does not seem to influence minimum standards of care as is defined by the set of cSLEQIs.
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Salient to the concept of quality indicators is the assumption that observance results in
improved disease control and long-term prognosis. Our study did not collect information on
disease activity or disease damage. Further no data are yet available in support of the notion
that consistent observance of the cSLE-QI is associated with improved cSLE outcomes.
Another limitation of the study is that there is a possibility of “volunteer” bias for the centers
that participated or that the centers that participated may not be representative of all sites
caring for cSLE patients. Among the seven participating sites in the study, two sites were
involved in the initial development of the cSLE-QI. Nevertheless, our study remains the first
to evaluate QI benchmarking among different international centers that care for cSLE
patients, and can serve as the basis for further quality improvement work that has been
largely lacking in cSLE.
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Reasons for non-performance of QI is often multifactorial and the result of factors pertaining
to patients and families, physicians and health care systems. Learning networks have been
developed to address quality improvement approaches in complex, multi-center health care
systems. An example from pediatric rheumatology may be PR-COIN (Pediatric
Rheumatology Collaborative Improvement Network), a learning collaborative of 13
pediatric rheumatology sites, currently focused on juvenile arthritis care (12). Within PRCOIN, patient education combined with improved disease monitoring and standards for
adjusting therapies have led to a measurable increase in the children with remission. Similar
efforts in cSLE seem necessary and beneficial to ensure improved evidence-based care of
children with cSLE.
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Significance and Innovations
•

This constitutes the first benchmarking effort for the observance of the recently
proposed cSLE quality indicators.

•

Performance of some quality indicators differs significantly among pediatric
rheumatology sites in the United States.

•

Smaller centers often have more difficulties in consistently adhering to the cSLE
quality indicators.
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Health Insurance

Medication

4 (4)
1 (1)

Asian
Other

* mean ± standard deviation. GCC-glucocorticoids.

4 (4)

45 (43)

Uninsured/unknown

56 (53)

Public insurance

10

66 (63)

Private Insurance

High-dose GCCs

Chronic GCC exposure

43

16 (15)

Black

Hispanics

84 (80)

White

2 (2)

20 (19)

85 (79)

39

51 (48)

5

1 (1)

7 (7)

42 (39)

57 (53)

2

2

Pregnancies in previous year

Race

85 (79)

88 (84)

Females

34 (32)

15 (14)

17

47 (45)

5 (5)

26 (24)

34

ISNPRS Class III or IV

Lupus nephritis

Major NPSLE features

Major organ involvement

4 (4)

Patients≥ 21 years

61 (57)

15

36 (34)

38

Newly-diagnosed patients in previous year
Patients ≥ 18 years

107

105

Number of patients

Values are N or N (%) unless stated otherwise;

†
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US 2

1 (2)

22 (37)

36 (61)

3

25 (42)

0

7 (12)

3 (5)

19 (32)

30 (51)

1

47 (80)

11

18 (31)

3 (5)

6 (10)

31 (53)

16

59

US 3
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US 1

1 (3)

14 (37)

23 (61)

2

22 (58)

16

2 (5)

2 (5)

14 (37)

20 (53)

0

32 (84)

12

17 (45)

0

3 (8)

10 (26)

5

38

US 4

43 (100)

25

39 (91)

57

11 (26)

0

6 (14)

26 (60)

0

38 (88)

5

13 (30)

6 (14)

0

19 (44)

2

43

Brazil 1

91 (89)

11 (11)

68

71 (69)

98

5 (5)

4 (4)

8 (8)

85 (83)

0

85 (83)

17

68 (66)

19 (18)

10 (23)

16 (18)

16

103

Brazil 2

28 (100)

3

16 (57)

0

28 (100)

0

17 (61)

12

20 (71)

1 (4)

2 (7)

5 (18)

3

28

India
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Demographics of the cSLE patients†
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72

53

QI 4: IF a patient has childhood-onset SLE, THEN education about sun avoidance should be documented at least once
in the medical record (e.g., wearing protective clothing, applying sunscreens whenever outdoors, and avoiding
sunbathing).

QI 5: IF an adolescent has childhood-onset SLE, THEN a transition plan should be carefully designed to facilitate
transfer of care to the appropriate adult health care providers.

Arthritis Care Res (Hoboken). Author manuscript; available in PMC 2017 February 01.
100

100

100
98
100
96

QI 7: IF a patient has newly diagnosed LN, THEN renal biopsy, urine sediment analysis, proteinuria, and kidney
function should all be assessed.

QI 8: IF a patient is diagnosed with proliferative childhood-onset SLE nephritis (WHO or ISN/RPS class III or IV),
THEN therapy with corticosteroids combined with another immunosuppressive agent should be provided and
documented within 1 month of this diagnosis, unless contraindicated‡

QI 9: IF a childhood-onset SLE patient without known LN has developed daily proteinuria of > 500 mg or clinically
relevant worsening of GFR/urinary sediment, THEN a kidney biopsy should be performed.

QI 10: IF a patient has known LN, THEN a clinical assessment for childhood-onset SLE should occur at least every 3
months, regardless of disease activity.

QI 11: IF a childhood-onset SLE patient has LN plus evidence of ongoing proteinuria >500 mg/day, THEN an ACEI
or ARB should be prescribed, unless there are contraindications.

QI 12: IF a patient has LN and/or hypertension, THEN disease co-management with a nephrologist should be
considered.

100 (31)

93

QI 13: IF a patient is prescribed a new medication for childhood-onset SLE (e.g., NSAIDs, DMARDs, or
glucocorticoids), THEN a discussion with the patient about the risks versus benefits of the chosen therapy should be
documented.

QI 14: IF a patient has childhood-onset SLE, THEN antimalarial therapy should be prescribed, unless there are
contraindications.

Domain 4: Medication Management

75

QI 6: IF a patient has a flare after having achieved remission of kidney disease, THEN diligent follow-up of renal
disease (kidney function, urine sediment, and proteinuria) every 3 months is needed.

Domain 3: Lupus Nephritis & hypertension management

100

92

N/A

US 1

QI 3: IF a patient has childhood-onset SLE, THEN vaccination against influenza should be prescribed, unless there
are contraindications.

Domain 2: General prevention

QI 2: IF a patient has confirmed childhood-onset SLE, THEN the laboratory studies should be obtained

QI 1: IF a patient has suspected childhood-onset SLE, THEN then laboratory studies should be obtained.

Domain 1: Laboratory testing around the time of diagnosis

Quality Indicators by Domain

Author Manuscript
Table 2

94

100 (14)

61

100

97

100

100

100

88

77

99

89

100

N/A

US 2

85

100 (8)

67

100

94

100

100

100

100

34

54

95

100

N/A

US 3

92

100 (5)

76

100

76

100

83

100

50

13

58

73

100

N/A

US 4

75

100 (2)

54

88

100

50

100

50

100

100

93

57

100

N/A

Brazil 1

95

100 (15)

68

94

100

54

94

54

98

100

88

97

100

N/A

Brazil 2

Author Manuscript

QI observance by participating pediatric rheumatology site†

100

60 (5)

67

80

100

100

100

100

0

0

58

0

100

N/A

India
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95

QI 20: IF a patient is receiving any steroid therapy, THEN calcium and vitamin D supplementation should be
recommended after 3 months.

94

QI 22: IF a childhood-onset SLE patient is treated with antimalarial therapy, THEN eye screening should be done at
least annually.

82

85

72

78

80

17

44

100

98

100 (3)

100

US 3

77

80

59

0

18

86

83

NA (NA)

100

US 4

82

78

97

60

90

97

97

42 (10)

64

Brazil 1

QI 26: IF a patient with childhood-onset SLE has major neuropsychiatric manifestations (optic neuritis, acute
confused state/coma, cranial or peripheral neuropathy, psychosis, and transverse myelitis/myelopathy), THEN
immunosuppressive therapy should be considered.

Domain 9: Neuropsychiatric Manifestations

QI 25: IF a patient with childhood-onset SLE is pregnant, THEN anti-SSA, anti-SSB, and antiphospholipid antibodies
should be documented in the medical record.

Domain 8: Pregnancy

80 (5)

50 (2)

2

60

Every 2 years: diabetes. hyperlipidemia

QI 24: IF a patient has childhood-onset SLE, THEN lifestyle modification (i.e. smoking cessation) is likely to be
beneficial for patient outcomes and should be encouraged

72

Every 1 year: Smoking, hypertension, high body mass index

100 (15)

100 (2)

78

97

97

100 (3)

100 (1)

10

18

38

-

-

82

15

21

100 (6)

-

94

100

100

QI 23: IF a patient has childhood-onset SLE, THEN education about cardiovascular risk factors should occur in regular intervals with the parent and the patient age ≥13 years

Domain 7: Education on Cardiovascular Risk Factors

95

QI 21: IF a childhood-onset SLE patient is treated with corticosteroids, THEN eye screening should be done at least
annually.

75

16

63

100

100

35 (6)

98

US 2

Values are % or % (N) unless stated otherwise. For a given QI, the number of patients are specifically mentioned if there are two at any of the sites.

†

8

QI 19: IF baseline bone mineral density testing is outside of the normal limits (Z scores of -2 or less), THEN bone
mineral density should be re-measured after 1 year.

Domain 6: Ophthalmological Surveillance

79

QI 18: IF a patient has received chronic systemic steroids, THEN the patient should have bone mineral density testing
documented in the medical record.

Domain 5: Bone Health

100

99

QI 17: IF a childhood-onset SLE patient is treated with medications, THEN laboratory surveillance for medication
safety should be done at regular intervals (complete blood count, renal and liver function test every 12 months)HCQ

GCC

71 (5)

QI 16: IF a patient with childhood-onset SLE is unable to decrease the dose of GCC acceptable for long-term use,
THEN the addition of a GCC-sparing agent or an increased dose of an existing GCC-sparing agent should be considered.

Author Manuscript
100

Author Manuscript

QI 15: IF a childhood-onset SLE patient is receiving a dose of steroids not acceptable for long-term use, then an
attempt should be made to taper steroids.

Author Manuscript
US 1

89 (19)

-

95

100

100

96

96

89

58

86

100

100

38 (5)

97

Brazil 2

Author Manuscript

Quality Indicators by Domain

100 (1)

-

10

0

0

94

93

100

0

7

100

89

25 (1)

75

India
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Author Manuscript

Author Manuscript

LN- lupus nephritis; GFR- glomerular filtration rate; Angiotensin receptor blocker-ARB; Angiotensin converting enzyme inhibitor- ACEI;HCQ-hydroxychloroquine; DEXA-Dual-energy X-ray
absorptiometry.

Author Manuscript

Based on patients who received kidney biopsy to confirm presence of proliferative LN.

Author Manuscript

‡
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Table 3

Differences in observance of the cSLE-QI between four US sites*

Author Manuscript

US sites
Range of Differences (%)

P-value‡

QI 3: Influenza vaccination

27

<.0001

QI 4: Photo protection

46

0.0039

QI 5:Transfer of care Planning

64

<.0001

QI 8:Treatment with immunosuppressive and GCC within 1 month of kidney biopsy

17

0.0151

QI 10: Clinical assessment of LN at least every 3 months regardless of disease activity

21

0.0151

QI 12: Nephrology co-management

33

0.0015

35

0.049

14/17

0.0002/<.0001

QI 18: DEXA for patients on chronic GCC.

61

<.0001

QI 20: Calcium and vitamin D supplementation when on GCC therapy for >3 months

67

0.0005

QI 21: Eye exams with GCC use

22

0.0345

QI 22: Eye exam with HCQ use

14

0.0158

Every 1 year: Smoking, hypertension, high body mass index

77

<.0001

Every 2 years: diabetes. hyperlipidemia

82

<.0001

80

<.0001

General prevention

Lupus Nephritis and Hypertension Management

Author Manuscript

Medication Management
QI 16: Addition of a GCC-sparing agent or an increased dose of an existing GCC-sparing
agent when unable to decrease GCC dose
QI 17: Safety labs with GCC/HCQ use**
Bone Health

Ophthalmological Surveillance

Education on Cardiovascular Risk Factors
QI 23: Education of Patient/Parent on CV risk factor, if patient ≥13 years

Author Manuscript

QI 24: Discussed smoking cessation, irrespective of patient age
*

Excluded were QI with fewer than 2 events;

**

every 3 months or less;

‡

Cochran- Mantel Haenzel test

Author Manuscript
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Table 4

Observance of cSLE-QI based on size of patient population

Author Manuscript

Large vs. small sites*
Difference (%)

P-value

QI 3: Influenza vaccination

95 vs. 64

<.0001

QI 4: Photo protection

64 vs. 36

0.0218

QI 5: Transfer of care Planning

76 vs. 41

<.0001

QI 6: Laboratory evaluations at least quarterly

94 vs. 46

<.0001

QI 7: Evaluations at diagnosis of LN

75 vs. 90

0.0152

QI 12: Nephrology co-management

76 vs. 49

0.0002

94 vs. 86

0.0044

General prevention

Lupus Nephritis and Hypertension Management

Author Manuscript

Medication Management
QI 14: HCQ use
QI 15: Attempt to taper GCC

78 vs. 69

<.0001

100/100 vs. 97/94

< 0.04

54 vs. 26

<.0001

QI 21: Eye exams with GCC use

92 vs. 80

0.0108

QI 22: Eye exam with HCQ use

91 vs. 81

0.0010

89/85 vs. 45/36

<.0001

QI 17: Safety labs with GCC/HCQ use
Bone Health
QI 18: DEXA for patients on chronic GCC
Ophthalmological Surveillance

Education on Cardiovascular Risk Factors
QI 23: Education of Patient/Parent on CV risk factor, if patient >13 years
*

Large sites treating ≥ 100 cSLE patients, otherwise considered small sites

Author Manuscript
Author Manuscript
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